A randomized clinical trial designed and intended to evaluate the efficacy of Dexamethasone and Methylprednisolone as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by coronavirus disease 19 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.
Drug: Dexamethasone
Injectable solution
Drug: Methylprednisolone
Injectable solution
Inclusion Criteria:
• Moderate to severe COVID-19 requires hospitalization. SARS-CoV-2 infection will be
confirmed by RT PCR / CT Chest in every case.
Exclusion Criteria:
- Participants with uncontrolled clinical status who were hospitalized from the before.
- Contraindication / possible drug interaction.
- Participants who have any severe and/or uncontrolled medical conditions like, Severe
ischemic heart disease, epilepsy, malignancy, Pulmonary/renal/hepatic disease,
pregnancy, Corpulmonale, etc.
Chattogram General Hospital
Chittagong, Bangladesh
M. Abdur Rahim Medical College Hospital
Dinajpur, Bangladesh
Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD
008801817711079
dr_mohiuddinchy@yahoo.com
Shubhashis Talukder, MBBS, DO
008801911882232
drshubhashis@gmail.com